▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2684 by analyst upside · 2026-09-27
JAZZ
Jazz Pharmaceuticals plc
Healthcare · Market Cap $15B · P/E 16.3x
ANALYST PRICE TARGET
+23.1%
implied upside to consensus target
Current Price $237.95
Consensus Target $292.81
Bull Target $337.0
Bear Target $225.0
Analysts Covering 21
ANALYST CONSENSUS - BUY
Strong Buy
7
Buy
12
Hold
2
Sell
0
52-Week Low $125.79
52-Week High $266.38
YTD Return +37.4%
FUNDAMENTALS
Market Cap $15B
P/E Ratio (TTM) 16.3x
Forward P/E 9.2x
EPS (TTM) $14.61
PEG Ratio 0.96
Dividend Yield N/A
Revenue (TTM) $4.6B
Profit Margin 20.4%
52-WEEK RANGE
52-Week Low $125.79
52-Week High $266.38
Current Price $237.95
Bear Target $225.0
Bull Target $337.0
● Now $237.95 ● Target $292.81
TRADING DATA
Avg Volume 862K
YTD Return +37.4%
Analyst Count 21
Consensus Buy
Upside to Target +23.1%
Last Updated 2026-09-27

ANALYST SUMMARY

Jazz Pharmaceuticals plc (JAZZ) is currently trading at $237.95 with a Wall Street consensus price target of $292.81, implying potential upside of 23.1% over the next 12 months. 21 analysts currently cover JAZZ, with a consensus rating of Buy - 90% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $337.0, while the most cautious has a target of $225.0.

JAZZ operates in the Healthcare sector with a market capitalisation of $15B. The stock is up 37.4% year-to-date and is currently trading near the upper end of its 52-week range of $125.79 – $266.38.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for JAZZ, with each firm's 90-day track record across all stocks we track. See full firm rankings →

UBS - Reiterated
Buy → Buy 2026-09-11 33% win rate (6 calls)
Barclays - Reiterated
Overweight → Overweight 2026-09-10 Building track record
Deutsche Bank - Reiterated
Buy → Buy 2026-08-26 Building track record
Morgan Stanley - Reiterated
Overweight → Overweight 2026-08-26 Building track record
Truist Securities - Reiterated
Buy → Buy 2026-08-26 Building track record
Needham - Reiterated
Buy → Buy 2026-08-26 20% win rate (5 calls)
Morgan Stanley - Reiterated
Overweight → Overweight 2026-08-11 Building track record
JP Morgan - Reiterated
Overweight → Overweight 2026-08-04 43% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
67
out of 100
Coverage depth
24/30
Consensus clarity
21/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →